Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

Phase 2 Unknown 75 enrolled Hongqian Guo

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.

Timeline

Start: 2018-12-12
Primary completion: 2020-12-01
Completion: 2023-01-01

Publications

Zhuang J, Wang Y, Zhang S, Fu Y, Huang H, Lyu X, Zhang S, Marra G, Xu L, Qiu X, Guo H. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. Front Pharmacol. 2023 Jun 26;14:1217303. doi: 10.3389/fphar.2023.1217303. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	5 mg	Oral
Background	Triptorelin	Other / unclassified	15 mg	—

Indications

No indication recorded.